|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0810 AUD | -1.22% |
|
+1.25% | -4.71% |
| 02/01 | FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate | MT |
| 02/01 | Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001 | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.37Cr | - | - | - | - | - |
| 96TCr | |||||
| 53TCr | |||||
| 39TCr | |||||
| 37TCr | |||||
| 30TCr |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition